Journal Reviews

Allergy journal cover image.

Biologicals for severe chronic rhinosinusitis with nasal polyps. Any use?

5 November 2021 | | ENTA-Rhinology / Sinus | chronic rhinosinusitis, dupilumab, mepolizumab, omalizumab, reslizumab

Recent advances and knowledge of inflammatory endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) led to introduction of biological agents such as monoclonal antibodies targeting IgE (omalizumab) and Interleukins (ILs) such as IL4R alpha (dupilumab) and IL5. The European Academy...